

MILLIONS OF LIVES. ONE MISSION.

Exploring the Potential of ADCs in Multiple Solid Tumours

Saturday 21 October 2023 | 13:00–14:30 CEST

León Auditorium, Hall 7, IFEMA MADRID, Madrid, Spain

Agenda

13:00–13:15

**Welcome and introduction:
ADCs – A journey across time**



Prof. Peter Schmid (UK)

Clinical Director, Breast Cancer Centre, St. Bartholomew's Hospital, London, Chair in Cancer Medicine, Barts Cancer Institute, Queen Mary University, London, UK

13:15–13:35

Improving the lives of patients with triple-negative and HR+/HER2- metastatic breast cancer



Dr Sara Tolaney (USA)

Chief of the Division of Breast Oncology, Dana-Farber Cancer Institute, Associate Professor of Medicine at Harvard Medical School, Boston, US

13:35–13:55

Unlocking the potential for the treatment of metastatic urothelial cancer



Prof. Thomas Powles (UK)

Director of Barts Cancer Institute, Professor of urology cancer, University of London, UK

13:55–14:10

Expanding opportunities in patients with metastatic NSCLC



Prof. Enriqueta Felip (Spain)

Head of Lung Cancer Unit, Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

14:10–14:30

Q&A and closing remarks

All faculty; facilitated by Chair Prof. Peter Schmid (UK)

ADCs, antibody-drug conjugates;
HER2, human epidermal growth factor receptor 2;
HR, hormone-receptor;
NSCLC, non-small cell lung cancer.

This non-promotional symposium is sponsored and organised by Gilead. Gilead's medicines will be discussed at this meeting. The purpose of this symposium is scientific exchange, the audience is encouraged to take active participation in the discussion throughout the symposium after each presentation by using voting system and live during Q&A.

GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc.

©2023 Gilead Sciences, Inc. All rights reserved
August 2023 | IHQ-TRO-0647

